Sight Sciences, Inc. (NASDAQ:SGHT) Shares Bought by Long Focus Capital Management LLC

Long Focus Capital Management LLC lifted its position in shares of Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 158.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,238,632 shares of the company's stock after acquiring an additional 1,373,535 shares during the quarter. Long Focus Capital Management LLC owned 4.41% of Sight Sciences worth $8,149,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. KCK LTD. purchased a new position in shares of Sight Sciences during the 4th quarter worth approximately $15,925,000. Geode Capital Management LLC raised its position in Sight Sciences by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 792,860 shares of the company's stock worth $2,887,000 after acquiring an additional 8,731 shares in the last quarter. State Street Corp lifted its holdings in Sight Sciences by 17.4% in the third quarter. State Street Corp now owns 646,776 shares of the company's stock valued at $4,075,000 after acquiring an additional 95,843 shares during the period. B Group Inc. purchased a new stake in shares of Sight Sciences during the 4th quarter worth $2,291,000. Finally, Renaissance Technologies LLC grew its stake in shares of Sight Sciences by 654.3% during the 4th quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock worth $1,431,000 after purchasing an additional 340,906 shares during the period. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Stock Performance

Sight Sciences stock opened at $2.99 on Wednesday. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $8.45. The company has a market capitalization of $153.49 million, a price-to-earnings ratio of -2.93 and a beta of 2.46. The stock has a fifty day moving average of $2.57 and a two-hundred day moving average of $3.47. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). The company had revenue of $19.07 million for the quarter, compared to analysts' expectations of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same quarter in the prior year, the business posted ($0.22) EPS. On average, analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Piper Sandler decreased their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Stifel Nicolaus dropped their price objective on Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Citigroup decreased their target price on Sight Sciences from $4.60 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, UBS Group dropped their price target on Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a research report on Monday, January 27th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $3.83.

Insider Activity at Sight Sciences

In related news, CEO Paul Badawi sold 24,174 shares of the company's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now directly owns 6,010,580 shares in the company, valued at approximately $13,824,334. This represents a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Manohar K. Raheja purchased 10,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the purchase, the executive vice president now owns 145,000 shares in the company, valued at $395,850. The trade was a 7.41 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 35,196 shares of company stock valued at $81,001. Company insiders own 28.90% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

Want to see what other hedge funds are holding SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sight Sciences, Inc. (NASDAQ:SGHT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.